Takeda Pharmaceutical Co. Ltd. (TKPYY) Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients With Newly Diagnosed Multiple Myeloma
5/23/2013 11:04:43 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant. The multi-center study with MLN9708, an investigational, oral proteasome inhibitor, will be conducted in Europe and North America.
Help employers find you! Check out all the jobs and post your resume.
comments powered by